Abstract
Endothelin (ET)-1 is a potent vasoconstrictor with profibrotic and proinflammatory effects. Increasing evidence suggests that ET-1 and its cognate receptors are involved in a variety of progressive renal disorders, including diabetes, hypertension and glomerulonephritis. Several laboratory studies have demonstrated elevated expression of ET-1, which colocalizes with glomerular and tubulointerstitial injury, in addition to enhanced urinary excretion. Moreover, ET-1 expression correlates with disease severity and renal function. With the availability of ET receptor antagonists, a pathogenetic role has been further corroborated in animal models, demonstrating both structural and functional improvement. Thus, antagonizing the ET system may be useful in major renal pathologies associated with glomerular and tubulointerstitial damage. © 2006 Oxford University Press.
Cite
CITATION STYLE
Richter, C. M. (2006). Role of endothelin in chronic renal failure - Developments in renal involvement. Rheumatology, 45(SUPPL. 3). https://doi.org/10.1093/rheumatology/kel278
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.